BioNTech, Genentech collaborate on personalized mRNA cancer vaccines
BioNTech AG licensed Roche's Genentech Inc. rights to develop, manufacture, and market personalized messenger RNA (mRNA) vaccines for multiple cancers.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com